news
European Antibody Congress 2015 comes to Basel
18 August 2015 | By The European Antibody Congress
The European Antibody Congress takes place 9-11 November 2015 at the Congress Centre, Basel...
List view / Grid view
Antibody Discovery
news
Round 8 of Biomedical Catalyst awards announced
10 August 2015 | By Charlotte Batchelor, Drug Target Review
Twelve new treatments, diagnostics and medical technologies will receive funding from the eighth round of the successful Biomedical Catalyst (BMC)...
news
MorphoSys and G7 Therapeutics to develop antibodies targeting GPCRs
4 August 2015 | By Victoria White
MorphoSys and G7 Therapeutics have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs)...
news
Researchers uncover the signals that govern the fate of TFH cells
31 July 2015 | By Victoria White
Researchers identify a pair of master regulators that control the fate of follicular helper T (TFH) cells - a finding that could improve vaccine design...
news
Inovio’s DNA-based monoclonal antibody (dMAb) protects against dengue
30 July 2015 | By Victoria White
Inovio’s DNA-based monoclonal antibody (dMAb) targeting dengue virus provided protection against a lethal dengue virus challenge in mice...
news
UMG and MRC Technology collaborate to develop Alzheimer’s therapy
28 July 2015 | By Victoria White
UMG and MRC Technology are to collaborate to develop a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x...
news
Regeneron and Sanofi launch major immuno-oncology collaboration
28 July 2015 | By Victoria White
Regeneron and Sanofi have entered into a new global collaboration to discover, develop and commercialise new antibody cancer treatments in immuno-oncology...
news
Discovery of cellular mechanism of action of tACPA in rheumatoid arthritis
11 June 2015 | By Victoria White
ModiQuest has discovered the cellular mechanism of action of its tACPA for the treatment of rheumatoid arthritis (RA) and other diseases...
article
Developing antibody therapeutics
Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…
news
MSD extends immuno-oncology collaboration with Agenus
3 June 2015 | By Victoria White
MSD has extended its existing collaborative research agreement with Agenus for the discovery and development of therapeutic antibodies...
news
Eureka Therapeutics and Boehringer Ingelheim enter into antibody research agreement
22 May 2015 | By Victoria White
Eureka Therapeutics and Boehringer Ingelheim have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology...
news
MabVax Therapeutics’ HuMab 5B1 antibody successfully clears important early toxicology testing
6 May 2015 | By Victoria White
The final report on toxicology testing of HuMab 5B1 shows that it had no significant adverse findings even at the highest dosage levels tested...
news
MRC Technology collaborates with NYU School of Medicine to develop biologics for inflammatory osteolysis
23 April 2015 | By Victoria White
MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown)...
news
Anaptysbio advances first-in-class anti-IL-36 receptor antibody, ANB019
17 April 2015 | By Victoria White
AnaptysBio has announced the advancement of its first-in-class anti-interleukin-36 receptor (IL-36R) antibody, ANB019, into IND-enabling studies.
article
Drug Targets In-Depth Focus 2015
9 April 2015 | By J.R.Costa, J.Heintze, R.Ketteler, S. Gul, Dr. T.Duensing, K.Papenfuss.
In this Drug Targets In-Depth Focus, we delve into the role of a key complex required for autophagosome maturation, the ATG4-ATG8 conjugation system, and we provide insight on some up-and-coming immune checkpoint inhibitors that are currently in clinical and preclinical development...
